WP5:characterisation of the back-up anti-HCV MAb

The goal of this work package will be to characterise in depth the back-up anti-HCV MAb by

  • Assessing the capacity of the back-up anti-HCV MAb to neutralise pseudotype viruses (HCVpp) representing diverse HCV genotypes

  • Assessing the capacity of the back-up anti-HCV MAb to neutralize infectioous clones of HCV (HCVcc)

  • Evaluating the E1E2-binding affinity of the back-up anti-HCV MAb

  • Mapping the E1E2-epitope(s) recognized by the back-up anti-HCV MAb

  • Sequencing the variable regions of the heavy and light chains of the back-up anti-HCV MAb

  • Determine the in vitro and in vivo neutralizing activity of the humanised antibody

Claudin